Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 윤채옥 | - |
dc.date.accessioned | 2019-11-19T05:26:27Z | - |
dc.date.available | 2019-11-19T05:26:27Z | - |
dc.date.issued | 2017-01 | - |
dc.identifier.citation | ONCOTARGET, v. 8, no. 3, page. 4730-4746 | en_US |
dc.identifier.issn | 1949-2553 | - |
dc.identifier.uri | http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=13972&path[]=44526 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/112280 | - |
dc.description.abstract | Interleukin (IL)-12 is a potent antitumor cytokine. However, immunosuppressive tumor microenvironments containing transforming growth factor-beta (TGF-beta) attenuate cytokine-mediated antitumor immune responses. To enhance the efficacy of IL-12-mediated cancer immunotherapy, decorin (DCN) was explored as an adjuvant for overcoming TGF-beta-mediated immunosuppression. We designed and generated a novel oncolytic adenovirus (Ad) coexpressing IL-12 and DCN (RdB/IL12/DCN). RdB/IL12/DCN-treated tumors showed significantly greater levels of interferon (IFN)-gamma, tumor necrosis factor-a, monocyte chemoattractant protein-1, and IFN-gamma-secreting immune cells than tumors treated with cognate control oncolytic Ad expressing a single therapeutic gene (RdB/DCN or RdB/IL12). Moreover, RdB/IL12/DCN attenuated intratumoral TGF-beta expression, which positively correlated with reduction of Treg cells in draining lymph nodes and tumor tissues. Furthermore, tumor tissue treated with RdB/IL12/DCN showed increases infiltration of CD8(+) T cells and proficient viral spreading within tumor tissues. These results demonstrated that an oncolytic Ad co-expressing IL-12 and DCN induces a potent antitumor immune response via restoration of antitumor immune function in a weakly immunogenic murine 4T1 orthotopic breast cancer model. These findings provide new insights into the therapeutic mechanisms of IL-12 plus DCN, making it a promising cancer immunotherapeutic agent for overcoming tumor-induced immunosuppression. | en_US |
dc.description.sponsorship | This work was supported by grants from the National Research Foundation of Korea (2015R1A2A1A13027811, 2013M3A9D3045879, and 2016M3A9B5942352). | en_US |
dc.language.iso | en | en_US |
dc.publisher | IMPACT JOURNALS LLC | en_US |
dc.subject | oncolytic adenovirus | en_US |
dc.subject | IL-12 | en_US |
dc.subject | decorin | en_US |
dc.subject | TGF-beta | en_US |
dc.subject | Treg | en_US |
dc.title | Oncolytic adenovirus coexpressing interleukin-12 and decorin overcomes Treg-mediated immunosuppression inducing potent antitumor effects in a weakly immunogenic tumor model | en_US |
dc.type | Article | en_US |
dc.relation.no | 3 | - |
dc.relation.volume | 8 | - |
dc.identifier.doi | 10.18632/oncotarget.13972 | - |
dc.relation.page | 4730-4746 | - |
dc.relation.journal | ONCOTARGET | - |
dc.contributor.googleauthor | Oh, Eonju | - |
dc.contributor.googleauthor | Choi, Il-Kyu | - |
dc.contributor.googleauthor | Hong, JinWoo | - |
dc.contributor.googleauthor | Yun, Chae-Ok | - |
dc.relation.code | 2017009424 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF ENGINEERING[S] | - |
dc.sector.department | DEPARTMENT OF BIOENGINEERING | - |
dc.identifier.pid | chaeok | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.